Authors

Angela C. Hirbe, MD, PhD, is an associate professor of medicine in the Division of Oncology at Washington University School of Medicine.

Latest:

Dr Hirbe on Long-Term Efficacy and Safety Outcomes With Mirdametinib in Symptomatic NF1-PN

Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.

Margaret E. Gatti-Mays, MD, MPH, FACP

Latest:

Dissecting Immunotherapy Options for TNBC

Margaret Gatti-Mays MD, MPH, of The James Cancer Hospital at Ohio State University, discusses the available immunotherapy options in triple-negative breast cancer.

Jack West, MD, City of Hope

Latest:

Review of AENEAS Trial and Similar Agents

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

Mark Yarchoan, MD

Latest:

Efficacy vs Toxicity With Immunotherapy

Panelists discuss how dual checkpoint inhibitors demonstrate significantly higher immune-related adverse event rates (nearly 30% grade 3-4) compared with atezolizumab-bevacizumab, but this increased toxicity is accompanied by meaningfully improved response rates, and the addition of anti-CTLA4 therapy roughly doubles response rates compared with anti-PD1 monotherapy in HCC.

Alexandra Sokolova

Latest:

Dr Sokolova on the Importance of Genetic Testing in Prostate Cancer

Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.

Elise Nassif, MD

Latest:

Dr. Nassif on Examining Gut Microbial Signatures in the Tumor Microenvironment

Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.

Christine Lovly, MD, PhD, FASCO

Latest:

Insights on Resistance Mechanisms and Sequencing Strategies for DLL3-Targeted and ADC Therapies in ES-SCLC

Panelists discussed advances in overcoming resistance in extensive-stage small cell lung cancer, highlighting promising antibody-drug conjugates and immune-based therapies targeting DLL3 and B7-H3, including bispecific T-cell engagers and CAR T cells, while emphasizing the critical need for biomarkers to guide therapy selection and optimize combinations to improve durability, intracranial activity, and patient outcomes amid the challenges of relapse and immune evasion.

Andrea Wolf, MD, MPH

Latest:

Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in Mesothelioma

Andrea Wolf, MD, MPH, discusses challenges experienced when conducting randomized trials to assess the role of surgery in mesothelioma management.

Colleen Moretti

Latest:

Darolutamide Plus ADT/Docetaxel Elicits Survival Benefit Across Subgroups in mHSPC

The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.

Ilyas Sahin, MD

Latest:

Dr Sahin on the Design of the Northstar Response Assay in Advanced GI Cancer

Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.

Anand Jillella, MD

Anand Jillella, MD, is the J. Harold Harrison, MD Distinguished University Chair in Medicine, a professor of medicine & pediatrics, and chief of the Division of Hematology/Oncology at Augusta University Medical College of Georgia. He is also associte director of Clinical Affairs and director of the Georgia Cancer Center Clinic, Ambulatory Services, and Network and Outreach

Latest:

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Helen Heng-Shan Moon, MD

Latest:

Dr. Moon on the Future of Care in Prostate Cancer

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Michelle T. Chi, MD

Latest:

Practical Considerations for Fellows Treating VTE

Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.

Michael Atkins, MD

Latest:

Dr Atkins on the Rationale of Investigating Nivolumab/Ipilimumab in RCC

Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.

Ruby Arora, MD

Ruby Arora, MD, is a resident physician of internal medicine in the Department of Medicine at the University of Illinois College of Medicine.

Latest:

Dr Arora on the Declining Incidence of MCL in the United States

Ruby Arora, MD, discusses the declining incidence of MCL in the US, as well as ways to address disparities that remain in MCL management.

Mark Alwardt

Latest:

Oral Oncolytics Will Require Health Care System to Adapt

Judging from the drug pipeline, the future of oncology is oral chemotherapy.

Allison A. DiPasquale, MD

Latest:

Dr DiPasquale on the Continued Investigation into Cerianna PET Scans in Breast Cancer

Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.

Ricardo Costa, MD, MSc

Latest:

Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

Stephen Hursting, PhD, MPH

Latest:

Dr Hursting on Weight Loss Drugs and the Potential to Reduce Obesity-Related Breast Cancer

R. Tyler Hillman, MD, PhD

R. Tyler Hillman, MD, PhD, is assistant professor in the Department of Gynecologic Oncology and Reproductive Medicine of the Division of Surgery at The University of Texas MD Anderson Cancer.

Latest:

Dr Hillman on Identifying New Therapy Candidates in Adult-Type Granulosa Cell Tumor

R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.